The CHA2DS2-VASc score is a reliable tool used to estimate the risk of ischemic stroke (IS) in patients with atrial fibrillation (AF). Few tools exist for the prediction of new-onset AF (NOAF) after myocardial infarction (MI) and its relation to IS. We studied the usefulness of CHA2DS2-VASc in predicting NOAF and IS in a long-term follow-up after MI. Consecutive MI patients without baseline AF (n = 70,922; mean age: 68.2 years), discharged from 20 hospitals in Finland during 2005-2018, were retrospectively studied using national registries. The outcomes of interest after discharge were NOAF- and IS-assessed with competing risk analyses at one and ten years. The median follow-up was 4.2 years. The median baseline CHA2DS2-VASc score was 3 (IQ...
AbstractBackgroundCHA2DS2-VASc score is the most widely preferred method for prediction of stroke ri...
BACKGROUND: Stroke risk in atrial fibrillation (AF) is often assessed at initial presentation, and r...
BackgroundDespite progresses in the treatment of the thromboembolic risk related to atrial fibrillat...
The CHA2DS2-VASc score is a reliable tool used to estimate the risk of ischemic stroke (IS) in patie...
Background: Patients with myocardial infarction (MI) are at risk of the development of atrial fibril...
Purpose Atrial fibrillation (AF) is a significant independent risk factor for 1-year mortality in pa...
Background: Atrial fibrillation confers a high risk of stroke and is associated with significant mor...
PURPOSE: Despite undergoing successful catheter ablation of typical atrial flutter (AFL), patients r...
SummaryBackground and methodsThe CHA2DS2-VASc score has been newly proposed for stratifying patients...
Introduction: The CHA2DS2-VASc and R2-CHA2DS2-VASc scores were initially designed to evaluate the ri...
PurposeAtrial fibrillation (AF) is a significant independent risk factor for 1-year mortality in pat...
AIMS: The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with n...
AIMS: The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with n...
Importance: The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled],...
AbstractBackgroundThe CHA2DS2VASc score has been used to evaluate the risk of thromboembolic events ...
AbstractBackgroundCHA2DS2-VASc score is the most widely preferred method for prediction of stroke ri...
BACKGROUND: Stroke risk in atrial fibrillation (AF) is often assessed at initial presentation, and r...
BackgroundDespite progresses in the treatment of the thromboembolic risk related to atrial fibrillat...
The CHA2DS2-VASc score is a reliable tool used to estimate the risk of ischemic stroke (IS) in patie...
Background: Patients with myocardial infarction (MI) are at risk of the development of atrial fibril...
Purpose Atrial fibrillation (AF) is a significant independent risk factor for 1-year mortality in pa...
Background: Atrial fibrillation confers a high risk of stroke and is associated with significant mor...
PURPOSE: Despite undergoing successful catheter ablation of typical atrial flutter (AFL), patients r...
SummaryBackground and methodsThe CHA2DS2-VASc score has been newly proposed for stratifying patients...
Introduction: The CHA2DS2-VASc and R2-CHA2DS2-VASc scores were initially designed to evaluate the ri...
PurposeAtrial fibrillation (AF) is a significant independent risk factor for 1-year mortality in pat...
AIMS: The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with n...
AIMS: The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with n...
Importance: The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 years [doubled],...
AbstractBackgroundThe CHA2DS2VASc score has been used to evaluate the risk of thromboembolic events ...
AbstractBackgroundCHA2DS2-VASc score is the most widely preferred method for prediction of stroke ri...
BACKGROUND: Stroke risk in atrial fibrillation (AF) is often assessed at initial presentation, and r...
BackgroundDespite progresses in the treatment of the thromboembolic risk related to atrial fibrillat...